Idorsia Pharmaceuticals Ltd.
Quick facts
| Founded | 2017 |
|---|
Phase 3 pipeline
- ACT-129968 · Neurology / Sleep Medicine
ACT-129968 is a selective orexin 2 receptor antagonist that promotes sleep by blocking wake-promoting signals in the brain.
Phase 2 pipeline
- ACT-539313 · Psychiatry
ACT-539313 is a selective dopamine D2 receptor antagonist. - ACT-541468 · Sleep disorders
ACT-541468 is a selective orexin receptor antagonist. - ACT-709478 for oral use · Psychiatry
ACT-709478 is a selective dopamine receptor D2/D3 antagonist.
Phase 1 pipeline
- AC-082
- AC-083
- ACT-1004-1239
- ACT-1014-6470
- ACT-132577
- ACT-389949 200 mg
- ACT-451840:
- ACT-451840 1000 mg
- ACT-451840 200 mg
- ACT-709478
- ACT-709478 combined with midazolam
- ACT541468
- ID-082
- ID-085
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Idorsia Pharmaceuticals Ltd.
What is Idorsia Pharmaceuticals Ltd.'s pipeline?
Idorsia Pharmaceuticals Ltd. has 1 drugs in Phase 3, 3 in Phase 2, 14 in Phase 1. Late-stage candidates include ACT-129968.
When was Idorsia Pharmaceuticals Ltd. founded?
Idorsia Pharmaceuticals Ltd. was founded in 2017.
Related
- Sector hub: All tracked pharma companies